Suchen
Repligen Corp
RGENZur Watchlist hinzufügen
141.010USD
-2.590-1.80%
Handelsschluss 07-31 16:00（ET）Kurse um 15 Minuten verzögert
7.94BMarktkapitalisierung
154.37KGV TTM
mehr Informationen über Repligen Corp Unternehmen
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.
Repligen Corp Informationen
BörsenkürzelRGEN
Name des UnternehmensRepligen Corp
IPO-datumApr 29, 1986
CEOLoeillot (Olivier)
Anzahl der mitarbeiter1778
WertpapierartOrdinary Share
GeschäftsjahresendeApr 29
AddresseBuilding 1, Suite 100
StadtWALTHAM
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl02453
Telefon17814499560
Websitehttps://www.repligen.com/
BörsenkürzelRGEN
IPO-datumApr 29, 1986
CEOLoeillot (Olivier)
Führungskräfte von Repligen Corp
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Karen A. Dawes
Ms. Karen A. Dawes
Lead Independent Director
Lead Independent Director
92.82K
+1.07%
Mr. Glenn P. Muir
Mr. Glenn P. Muir
Independent Director
Independent Director
40.05K
+8.56%
Mr. Ralf Kuriyel
Mr. Ralf Kuriyel
Senior Vice President - Research and Development
Senior Vice President - Research and Development
9.42K
-28.60%
Mr. Nicolas M. Barthelemy
Mr. Nicolas M. Barthelemy
Independent Director
Independent Director
5.44K
+18.30%
Mr. Rohin Mhatre, Ph.D.
Mr. Rohin Mhatre, Ph.D.
Independent Director
Independent Director
5.01K
+19.84%
Mr. Olivier Loeillot
Mr. Olivier Loeillot
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.22K
-155.54%
Ms. Carrie Eglinton Manner
Ms. Carrie Eglinton Manner
Independent Director
Independent Director
--
--
Mr. James R. Bylund
Mr. James R. Bylund
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Konstantin Konstantinov, Ph.D.
Dr. Konstantin Konstantinov, Ph.D.
Independent Director
Independent Director
--
--
Dr. Martin D. Madaus, Ph.D.
Dr. Martin D. Madaus, Ph.D.
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Karen A. Dawes
Ms. Karen A. Dawes
Lead Independent Director
Lead Independent Director
92.82K
+1.07%
Mr. Glenn P. Muir
Mr. Glenn P. Muir
Independent Director
Independent Director
40.05K
+8.56%
Mr. Ralf Kuriyel
Mr. Ralf Kuriyel
Senior Vice President - Research and Development
Senior Vice President - Research and Development
9.42K
-28.60%
Mr. Nicolas M. Barthelemy
Mr. Nicolas M. Barthelemy
Independent Director
Independent Director
5.44K
+18.30%
Mr. Rohin Mhatre, Ph.D.
Mr. Rohin Mhatre, Ph.D.
Independent Director
Independent Director
5.01K
+19.84%
Mr. Olivier Loeillot
Mr. Olivier Loeillot
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.22K
-155.54%
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Repligen Corp?
Die fünf größten Anteilseigner von Repligen Corp sind: Ms. Karen A. Dawes
Wie viele Institutionen halten Anteile an Repligen Corp (RGEN)?
Mit Stand vom 2026Q1 halten 1067 Institutionen Anteile an Repligen Corp, mit einem Gesamtmarktwert von etwa 65.93M, was 116.89% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -2643397.00 gestiegen.
Was ist die größte Einnahmequelle von Repligen Corp?
Am 2026Q1 erzielte das Geschäft mit Product revenue - Filtration products für Repligen Corp den höchsten Umsatz in Höhe von 402.79M, was 54.58% des Gesamtumsatzes entspricht.